VAUGHAN, Ontario, April 26, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration has approved LUMIFY Preservative Free redness reliever eye drops, the first and only over-the-counter preservative-free eye drop with low-dose OTC brimonidine tartrate for the treatment of ocular redness due to minor eye irritations.

“LUMIFY Preservative Free significantly reduces redness within one minute and lasts up to eight hours," said John Ferris, executive vice president, Consumer, Bausch + Lomb. “We expect to make LUMIFY Preservative Free available for purchase at major retailers in early 2025 in single-use vials – a convenient on-the-go option for consumers who have sensitivities to preservatives.”

LUMIFY Preservative Free contains a unique formulation* and selectively targets redness, similar to LUMIFY. In clinical trials, LUMIFY Preservative Free was shown to have a low incidence of side effects, like rebound redness and loss of efficacy over time, when used as directed.

"LUMIFY is a proven redness reliever eye drop that I recommend to my patients,” said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, TN. “Now, with LUMIFY Preservative Free, my patients will have another convenient treatment option.”

###

About the LUMIFY Brand
The LUMIFY brand began in 2018 with the U.S. introduction of LUMIFY redness reliever eye drops, which are the first and only cover-the-counter eye drop formulated with low dose brimonidine tartrate 0.025% for the treatment of ocular redness. They are the No. 1 eye doctor recommended redness reliever eye drop brand with approximately 90% of doctor recommendations¹, and they have received more than a dozen awards, including Glamour's "The Best Beauty Innovators of 2022" award. In 2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS, a new line of specialty eye care products specifically developed for the sensitive area around the eyes. In April 2024, the FDA approved LUMIFY Preservative Free eye drops. For more information on the LUMIFY brand, visit www.lumifyeyes.com.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References

^1.IQVIA, Average Share of Weekly Doctor Recommendations, Jan – Dec 2023.

*low-dose OTC brimonidine

© 2024 Bausch + Lomb.
LUM.0052.USA.24

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735 

Source:- Bausch + Lomb